Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 11/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688137 | 0.77 | SLC6A2 (0.44) | SMN1; SMN2EPHX2 | |
| SCHEMBL1688142 | 0.70 | KHK (0.50) | SMN1; SMN2EPHX2 | |
| SCHEMBL9229962 | 0.69 | ALDH1A1 (0.45) | LMNA | |
| SCHEMBL15352816 | 0.69 | PKM (0.49) | CNR2 | |
| SCHEMBL15160352 | 0.63 | SLC6A2 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL21465864 | 0.63 | CA12 (0.52) | SLC6A9 | |
| SCHEMBL21287875 | 0.62 | ALDH1A1 (0.42) | SMN1; SMN2 | |
| SCHEMBL15621005 | 0.62 | GBA1 (0.63) | — | |
| SCHEMBL15158792 | 0.62 | SLC6A2 (0.40) | SMN1; SMN2 | |
| SCHEMBL13684206 | 0.60 | SLC6A9 (0.57) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |